Lichen planus market seen reaching $1.76 billion by 2030

The global lichen planus market is projected to grow from $1.26 billion in 2025 to $1.35 billion in 2026, then climb to $1.76 billion by 2030. The report points to rising autoimmune disease prevalence, more diagnosis, and expanding treatment options as key drivers.

Why it matters: - Lichen planus is a chronic inflammatory disorder that can affect the skin, mouth, nails, and hair, so demand for treatment spans dermatology and oral care. - The market outlook signals continued spending on therapies as autoimmune disease rates rise and long-term symptom management becomes more important.

What happened: - The Business Research Company released its Lichen Planus Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the lichen planus market will rise from $1.26 billion in 2025 to $1.35 billion in 2026, a 7.1% CAGR. - The market is projected to reach $1.76 billion by 2030, at a 6.8% CAGR. - The report says the growth outlook reflects stronger diagnosis rates, wider access to corticosteroid-based treatments, more dermatology specialty clinics, better clinical understanding, and greater use of phototherapy. - A free sample of the report is available. - A full report is also available.

The details: - Lichen planus causes flat, purplish, itchy bumps, often on the wrists, ankles, and lower back. - Oral lichen planus can appear as white, lace-like patches or painful sores inside the mouth. - The report identifies rising autoimmune disease prevalence worldwide as a major demand driver. - Autoimmune disorders cited in the report include rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. - The report links autoimmune disease growth to genetic factors that affect immune system regulation and connective tissue health. - The Australian Institute of Health and Welfare reported in June 2024 that about 514,000 people in Australia, or 2.0% of the population, were living with rheumatoid arthritis in 2022. - That condition accounted for 2.0% of total disease burden and 16% of musculoskeletal disease burden in 2023, with 1,322 deaths recorded in 2022. - North America held the largest share of the lichen planus market in 2025 and is expected to keep that lead through 2026. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Between the lines: - The forecast suggests the market is moving from basic symptom treatment toward more targeted and technology-enabled care. - Investment themes in the report point to immunotherapies, biologic treatments, targeted anti-inflammatory drugs, digital dermatology tools, and longer-term disease management. - The regional emphasis on North America suggests the strongest near-term commercial opportunity remains in markets with deeper specialty care infrastructure.

What's next: - The Business Research Company says the 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated trend analysis. - Future market growth will likely hinge on whether newer therapies and digital tools can improve diagnosis and chronic management at scale.

The bottom line: - Lichen planus remains a niche but growing healthcare market, with demand supported by autoimmune disease trends and a forecast that keeps expanding through 2030.